moomoo ID:NaN
Log Out
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > IOVA Iovance Biotherapeutics > Company Executives
IOVA Iovance Biotherapeutics
Post Mkt Price
NamePositionSalaryService DateEducationAgeGenderUpdated
Mr. Frederick G. Vogt, J.D.,PhDInterim Chief Executive Officer, President and General Counsel7.93M----48male04/27/2022
Dr. Igor P. Bilinsky, PhDChief Operating Officer4.52M----49male04/27/2022
Mr. Jean-Marc BelleminChief Financial Officer, Principal Accounting Officer and Treasurer1.52M----50male04/27/2022
Dr. Friedrich Graf FinckensteinChief Medical Officer4.28M----55male04/27/2022
Dr. Iain D. Dukes, D.Phil.Chairman of the Board1.16M----63male04/27/2022
General Merrill A. McPeakIndependent Director608.17K----86male04/27/2022
Dr. Michael Weiser,M.D.,PhDIndependent Director851.92K----59male04/27/2022
Mr. Ryan D. MaynardIndependent Director596.92K----52male04/27/2022
Dr. Athena Countouriotis, M.D.Independent Director596.92K----50female04/27/2022
Mr. Wayne RothbaumIndependent Director240.00K----54male04/27/2022
Company Overview More
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.
CEO: Mr. Frederick G. Vogt, J.D.,PhD
Market: NASDAQ
Listing Date: 02/26/2015
Hot List
SymbolLatest price%Chg